Shanghai, April 10, 2025 – Luye Pharma Group announced the recent launch of its rotigotine transdermal patch, Rotigotine Luye, in the UK. This product is indicated for the treatment of the signs and symptoms of early-stage and advanced idiopathic Parkinson's disease (PD) as well as moderate-to-severe idiopathic restless legs syndrome (RLS) in adults. Rotigotine Luye is the first generic transdermal patch launched in the UK demonstrating bioequivalence to Neupro®.[1]
Rotigotine Luye patches and Neupro patches have the same dosage strengths. At the equivalent dosage strength, a Rotigotine Luye patch is 8% smaller in size and has a lower drug load compared to a Neupro® patch.[2],[3] Furthermore, unlike Neupro® patches, the adhesive substrate of Rotigotine Luye patches does not contain sodium metabisulfite, a known contact allergen that may cause allergic reactions.[3],[4]
PD is the second most common neurodegenerative disorder worldwide, affecting over 10 million people.[5],[6] This condition leads to impaired mobility as well as a range of other health issues such as mental disorders, sleep disorders, and pains, with symptoms progressively worsening over time, which significantly compromise the patients' well-being and quality of life.[7] RLS is a common neurosensory disorder affecting approximately 3% of the global population. Characterized by an overwhelming and irresistible urge to move legs, this condition can significantly disrupt the daily activities of patients in severe cases.[8],[9] Rotigotine, which acts as a dopamine agonist, can improve the motor function and non-motor function of PD patients and can provide an effective symptom relief for those with RLS.
Andy Farrant, General Manager of Luye Pharma Ltd., said: “PD and RLS significantly compromise the quality of life for patients and exert a heavy burden to their caregivers. The launch of Rotigotine Luye expands therapeutic options for patients. It is the sixth product launched by Luye Pharma in the UK, reaffirming our long-term commitment to the central nervous system (CNS) therapeutic area and our dedication to public health.”
In addition to the UK, Rotigotine Luye has been launched in Germany. The company plans to launch this product in several other countries with partners. Rotigotine Luye is produced by Luye Pharma’s manufacturing facility in Germany. This facility has specialized in transdermal drug delivery technology for over 20 years and is currently one of the largest independent manufacturers of transdermal patches in Europe.
About Rotigotine Luye
Rotigotine Luye is indicated for the treatment of:
Restless Legs Syndrome (RLS): for the symptomatic treatment of moderate-to-severe idiopathic RLS in adults.
Parkinson’s Disease (PD): as a monotherapy for early-stage idiopathic PD or used in combination with levodopa for advanced PD when the efficacy of levodopa diminishes or becomes unstable ("on-off" fluctuations).
TOP